Abstract: The potential beneficial effects of the antioxidant properties of vitamin C have been investigated in a number of pathological conditions. In this review, we assess both clinical and preclinical studies evaluating the role of vitamin C in cardiac and vascular disorders, including coronary heart disease, heart failure, hypertension, and cerebrovascular diseases. Pitfalls and controversies in investigations on vitamin C and cardiovascular disorders are also discussed.

Keywords: ascorbic acid; blood pressure; coronavirus; COVID–19; dietary supplements; drug formulations; endothelial dysfunction; GULO; heart failure; hypertension; infections; liposomes; oxidative stress; stroke; SVCT; vascular permeability; Vitamin C

1. Physiology of Vitamin C

Vitamin C is a carbohydrate-like substance first isolated in 1928 by Albert Szent-Györgyi from cabbage, paprika, and the adrenal glands of some animals [1,2]; it was later found to be identical with the antiscorbutic factor that had been isolated from lemon juice by Sylvester Solomon Zilva in 1924 [3]. Originally called ‘hexuronic acid’ by Györgyi, the current denomination as vitamin C was proposed in 1933 by Walter Norman Haworth [4,5].

Among the vastly biological functions in which vitamin C is involved, as a potent antioxidant and radical scavenger, it protects cell constituents against oxidative stress, mediated by reactive oxygen species (ROS) and free radicals [6–8]. Moreover, vitamin C redox potential allows the maintenance of reduced and regeneration of other antioxidants, including glutathione and α-tocopherol (vitamin E) [9–11]. It is also required for the synthesis of several crucial biomolecules since it acts as a cofactor of the monoxygenase and dioxygenase enzymes [12]. Vitamin C-dependent enzymatic reactions are involved in the biosynthesis of collagen and cellular procollagen secretion, L-carnitine, norepinephrine, epinephrine, and for the regulation of the biosynthesis of other molecules [13,14]. Furthermore, vitamin C intake from food or supplements can increase the bioavailability of iron by improving the absorption of the non-heme iron [15–18].
2. Genetics and Diet

The crucial biological functions of vitamin C and the severity of the pathological consequences of its deficiency somehow explain the evolutive conservation of its biosynthesis within the great part of the mammalian class, as well as in many vertebrate animals [19]. However, this ancestral function has been lost during the evolution in humans, anthropoid primates, guinea pigs, and some species of monkeys and bats [20,21]. Albert Lehninger between the 1950s and 1960s was the first scientist to indicate that human cells are not able to perform the last reaction of vitamin C biosynthesis, i.e., the conversion of L-gulono-γ-lactone into ascorbic acid, which is catalyzed by the enzyme L-gulono-γ-lactone (GULO) oxidase [21–23]. It was only in 1991 that Nishikimi and colleagues demonstrated that the gene encoding for GULO is still present in humans but is not active due to the accumulation of a number of mutations that eventually turned it into a non-functional pseudogene [24,25]. Biochemists are continuing to investigate the exact reasons that led to the propagation of this inborn genetic flaw, namely the loss of a gene coding for an essential compound, during the evolution from a primate ancestor to humans. Although several mechanisms were proposed, the primary argument supporting the paradox that mammalian species with the loss-of-function mutations of the GULO gene were not under selective pressure is that all these species have diets that provide a high amount of vitamin C; therefore, the loss of their GULO gene did not cause any evolutive disadvantage [20,26–28]. This explanation is in agreement with the fact that wild anthropoid primates consume a considerably larger quantity of vitamin C per body weight compared to the human recommended daily amount for vitamin C (65 to 90 mg/day) [29]: dietary intake of vitamin C reported for gorillas (Gorilla gorilla) is 20–30 mg/kg/day, for spider monkeys (Ateles Geoffroyi) is 106 mg/kg/day, and for howler monkeys (Alouatta palliata) is 88 mg/kg/day; similar considerations are valid for bats, with Artibeus jamaicensis consuming 258 mg/kg/day [20,28].

Based on the Third National Health and Nutrition Examination Survey (NHANES III, 1988–1994), the percentage of US males with vitamin C deficiency (less than 11.4 µmol/L in serum) was found to be greater compared to females, reaching a peak of 17% among 25- to 64-year-old subjects [30]. The more recent 2003–2004 NHANES revealed the one vitamin C status improved in the US population, and vitamin C deficiency was significantly lower than that observed during NHANES III; indeed, the overall prevalence of age-adjusted vitamin C deficiency was 7.1 ± 0.9% [31]. Yet, various studies have evidenced low vitamin C levels in both adults and children living in low-income countries [32–35]. In India, vitamin C deficiency has been relatively well characterized by large population-based studies of >5600 adults aged over 60, in which a marked deficiency was observed in 74% of adults living in north India and 46% of adults living in south India [32,36].

3. Pharmacokinetics and Bioavailability of Vitamin C

Vitamin C is a lactone (C_6H_8O_6) and can exist both in a reduced and in an oxidized form: L-ascorbic acid (reduced form) and dehydro-L-ascorbic acid (oxidized form), as shown in Figure 1. Its hydroxyl groups are located at positions 2 and 3 ionize with pK values of 4.17 and 11.57. Although both forms are biologically active [37,38], in most body fluids, reduced vitamin C is mainly present as an ascorbate anion [39–41]. Due to its size and charge, ascorbate does not readily permeate the lipid bilayer [42–44]. The majority of intestinal uptake, tissue distribution, and renal reuptake is mediated by the Na^+-dependent vitamin C transporters (SVCT1 and SCVT2), which co-transport Na^+ and ascorbate across membranes: SVCT1 is widely distributed, while SVCT2 is the main isoform in the adrenal gland and in the eye [45–55].

Ingested vitamin C is mostly absorbed across the intestinal epithelium by membrane transporters in the apical brush border membrane, either as ascorbate via the SVCT transporters or as dehydroascorbic acid through facilitated diffusion via GLUT1 or GLUT3 transporters [56–58]; once inside the cell, dehydroascorbic acid is then converted to ascorbate or transported to the bloodstream by GLUT1 and GLUT2 in the basolateral membrane. Specifically, SVCT1 is mainly located on the apical membrane of enterocytes whereas SVCT2 is expressed at the basolateral surface [59–64]. SVCT1 is also present in the epithelium of the proximal renal tubuli [50], where it orchestrates the active reabsorption of
ascorbate in the kidneys. A murine model lacking SVCT1 exhibited a significantly increased (18-fold) renal fractional excretion, though intestinal absorption was not reduced [65], indicating that the renal SVCT1-mediated reabsorption of vitamin C is crucial in determining its systemic homeostasis.

The non-linear pharmacokinetics and the unique compartmentalization of vitamin C at physiological levels [50,66–69] can be mostly attributed to the differences between organs in expression, concentration dependency, and substrate affinity of the SVCT and GLUT transporters [49,57,60–62,70–72]. In contrast to oral administration, parenteral administration of vitamin C bypasses the saturable transport mechanism that governs its intestinal absorption [73,74]. However, intravenous administration of vitamin C is an impractical mode of administration and carries risks of discomfort, infection, and phlebitis. Hence, alternative modes of effective vitamin C delivery have been proposed, with the ultimate goal of improving its bioavailability. In this regard, oral consumption of vitamin C encapsulated in liposomes may hold promise. Liposomes consist of single or multiple concentric membrane-like phospholipid bilayers encapsulating an aqueous compartment [75–78]. The size of these lipid vesicles can range from a few nanometers to several micrometers; liposomes specifically applied to medical use range between 50 and 450 nm [78–81]. Liposomes seem to be an ideal drug-carrier system, since their morphology is similar to that of cellular membranes and because of their ability to incorporate various substances, including hydrophilic molecules [82–100]. Accordingly, several studies have indicated that liposomes are very useful for delivering vitamin C [99,101–115]. For instance, Davis and coworkers evaluated plasma levels of oral, intravenous, and liposomal vitamin C, demonstrating that liposomal vitamin C has an enhanced bioavailability compared to non-liposomal vitamin C, while avoiding the risks associated with intravenous administration [116]. Another recent study has demonstrated that liposomal vitamin C increases the concentration of vitamin C in the blood by almost doubling the concentration obtainable via the non-liposomal form [117]. These results imply that liposomes might be an excellent carrier for vitamin C to achieve high blood levels.

4. Cardiovascular Effects of Vitamin C: Pre-Clinical Evidence

Severe vitamin C deficiency leads to a well-established disease, known as scurvy, a pathological condition characterized by bleeding, poor wound healing, hair and tooth loss, joint pain, and bone fragility [4]. Albeit scurvy is a fatal disease if not promptly treated, in several clinical studies, low levels of vitamin C (assessed by dietary intake or plasma analysis) have been associated with a number of conditions, including high blood pressure (BP), endothelial dysfunction, heart disease, atherosclerosis, and stroke [118–121]. Several pre-clinical studies investigated the role of vitamin C in cardiac and vascular protection and in the amelioration of pathological conditions. In 1999, Heller and
collaborators demonstrated that ascorbic acid potentiates nitric oxide (NO) synthesis in cultured human endothelial cells, a mechanism that can preserve vessels from altered myogenic tone (vasoconstriction), atherosclerosis, and coagulation abnormalities [122]. Huang et al., in 2000, reported similar effects on the endothelium-derived NO synthase (eNOS) bioactivity, through the increase of the intracellular tetrahydrobiopterin content in porcine aortic endothelial cells [123]. These results were then confirmed by Baker et al., who reported a significant enhancement of eNOS enzymatic activity in human umbilical vein endothelial cells (HUVECs) treated with vitamin C, following the increase of the eNOS cofactor tetrahydrobiopterin [124].

Similar protective effects of vitamin C on vascular endothelial functions were reported in 2002 by d’Uscio et al., who observed that supplementation with ascorbate increases tetrahydrobiopterin and eNOS activity in the aortas of apoE-deficient and control mice [125]. Further evidence of the endothelial protection derived by vitamin C and tetrahydrobiopterin was provided later by Yan et al., who reported in a rat model that oral co-supplementation of vitamin C with tetrahydrobiopterin and L-arginine significantly increases vascular perfusion after hindlimb ischemia by augmenting eNOS activity and reducing oxidative stress and tissue necrosis [126].

In 2003, Ülker and collaborators reported that incubation of aortas from spontaneously hypertensive rats with different concentrations of vitamin C (10 to 100 µmol/L) improved endothelial function, reduced NAD(P)H oxidase activity, as well as superoxide production, and increased eNOS activity and NO generation to the levels observed in control rat aortas [127].

These observations were corroborated by Ladurner et al., who discovered that ascorbate rapidly activates eNOS in HUVEC and immortalized human endothelial cells, through a dose-dependent increased phosphorylation of eNOS-Ser1177 and concomitant decreased phosphorylation at eNOS-Thr495 [128], a phosphorylation pattern highly indicative of increased eNOS activity [129]. Glutathione in its reduced form (GSH) plays crucial roles in protecting cells from oxidative damage, as well as in maintaining cellular redox homeostasis [130,131]. GSH is essential for the physiological function of vitamin C because it is required in vivo for the reduction of dehydroascorbate in guinea pigs, unable to synthesize ascorbate [132]; moreover, GSH deficiency in adult mice stimulates ascorbate synthesis in the liver [132]. These findings strongly suggest the presence of a metabolic redundancy and overlap in the functions of these two important antioxidants [133].

While optimal levels of plasma vitamin C may be critical for maintaining glutathione in its reduced form, sparing it from depletion [134,135], the increment of the oxidized glutathione (GSSG) in the heart, with the consequent reduction of the GSH/GSSG ratio, could lead to ventricular arrhythmias via mechanisms that include mitochondrial depolarization in cardiomyocytes [136].

Overall, these observations indicate that vitamin C does not exert its antioxidative function only by direct interaction with ROS but also via maintenance of the redox regulation by increasing levels of other cellular radical scavengers.

5. Vitamin C and Cardiac Disease

Various clinical studies have investigated the association between supplementation of vitamin C and the risk of cardiovascular disease (CVD), heart failure (HF), coronary heart disease (CHD), and other major adverse cardiac events (Tables 1 and 2), often yielding opposite results.

In 1993, Rimm et al. published a cohort study conducted on 39,910 US health professionals free of diagnosed CHD or other metabolic conditions at enrollment, and assessed by dietary questionnaires the intake of vitamin C, vitamin E, and carotene, showing that vitamin C (1162 mg/day) was not associated with a lower risk of CHD during a 4-year follow-up [137]. However, in 2003, a study conducted on 85,118 female nurses, based on a food-frequency questionnaire and using multivariate models to adjust for age, smoking, and other cardiovascular risk factors, indicated that the intake of vitamin C supplements was associated with a significantly lower risk of CHD during 16 years of follow-up [138].
Table 1. Major studies investigating the association between vitamin C and cardiovascular disease (CVD).

| Clinical Study                          | Study Population                                      | Vitamin C Concentration Range | Fasting Blood Sample (Assay Used)                                           | Adjustments                                                                 | Outcome                                                                                     | Ref.       |
|-----------------------------------------|-------------------------------------------------------|-------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-----------|
| EPIC-Norfolk                            | 19,496 healthy men and women from Norfolk (US)        | 25.9–79.2 µmol/L             | Non-fasting venous blood (fluorometric assay)                               | Age, systolic BP, cholesterol, smoking, diabetes, and supplement use         | A mean follow-up of 4 years showed that 20 µmol/L rising in plasma Vitamin C concentration was associated with ~20% reduced risk of all-cause mortality | [121,139] |
| EPIC-Norfolk                            | 20,299 healthy men and women from Norfolk (US)        | 41–66 µmol/L                 | Non-fasting venous blood (fluorometric assay)                               | Age, sex, smoking, BMI, physical activity, systolic BP, diabetes, cholesterol, MI, social class, alcohol, and supplement used | A mean follow-up of 12.8 years showed that every 20 µmol/L increase in plasma Vitamin C was associated with a 9% relative reduction in the risk of HF | [140]    |
| HPFS—Health Professionals Follow-up Study | 39,910 healthy US male, health professionals         | 95–116 mg/dL.               | Not reported                                                                | Age, season, smoking, energy intake, alcohol, hypertension, history of MI, profession, BMI, and physical activity | After a mean follow-up of 8 years, Vitamin C intake was not associated with a lower risk of CHD and stroke | [141]    |
| NHS I—Nurses’ Health Study I           | 85,118 healthy US female nurses                       | 70–704 mg/dL.               | Not reported                                                                | Age, energy intake, supplements use, alcohol, smoking status, and diabetes  | Data from 16 years of follow-up indicate that Vitamin C supplement is associated with a significantly lower risk of CHD | [138]    |
| ASAP—Antioxidant Supplementation in Atherosclerosis Prevention | 520 men and post-menopausal women, with hyper-cholesterolemia | Not specified               | Not specified (HPLC assay)                                                  | Sex, baseline HDL cholesterol                                               | A 6-year follow-up indicated that Vitamin C supplementation reduced the slope of the mean carotid artery intima-media thickness progression | [142]    |
| Women’s Antioxidant Cardiovascular Study | 8171 female health professionals with CVD, or 3 or more CVD risk factors | Not specified               | Not reported                                                                | Compliance-adjusted analyses                                               | After a follow-up of 9.4 years, no overall effects of Vitamin C (500 mg/day) on all major cardiovascular events and stroke | [143]    |
| NHANES II                               | 8417 US men and women                                 | 17–79.5 µmol/L              | Non-fasting venous blood (colorimetric assay)                              | Age, sex, race, education, physical activity, dietary energy and fat intake, cholesterol, BMI, alcohol, smoking, diabetes, hypertension, CHD, stroke, cancer, use of aspirin, Vitamin E intake | Decreased risk of all-cause mortality                                                   | [144]    |
| NHANES III                              | 6624 US men and women                                 | 17–85.2 µmol/L              | Non-fasting venous blood (colorimetric assay)                              | Age, sex, race, education, physical activity, smoking, alcohol, cholesterol, BMI, diabetes, hypertension, use of aspirin, Vitamin E intake | Top Vitamin C group had a 27% lower CVD risk compared to bottom group                  | [145]    |
Table 1. Cont.

| Clinical Study                        | Study Population | Vitamin C Concentration Range | Fasting Blood Sample (Assay Used) | Adjustments                                                                 | Outcome                                                                 | Ref. |
|---------------------------------------|------------------|-------------------------------|-----------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------|------|
| SU.VI.MAX study                       | 13,017 French adults | Not specified                 | Fasting venous blood              | Bonferroni adjustment for multiple mean comparisons                       | After a follow-up of 7.5 years, no effect of Vitamin C supplementation (120 mg/d) on CVD; lower all-cause mortality in men | [146] |
| PHS II—Physicians Health Study II     | 14,641 healthy US male physicians | Not specified                 | Not reported                      | Age, PHS cohort, randomized β-carotene, Vitamin E or Vitamin C, and multivitamin assignments | A mean follow-up of ~8 years showed that Vitamin C supplementation (500 mg/day) had no significant effect on the incidence of CVD, stroke, or mortality for cardiovascular events | [147] |
| Heart Protection Study                | 20,536 British men and women with CHD, occlusive arterial disease, or diabetes | Not specified                 | Non-fasting venous blood          | Not specified                                                              | After a follow-up of 5 years, Vitamin C supplementation (250 mg/d) had no significant effects on CVD | [146] |
| CARDIA                                | 2884 healthy US men and women | 24–70 µmol/L                 | Fasting venous blood (HPLC assay) | Age, sex, race, center, education, smoking, alcohol, physical activity, a priori diet quality score and food consumption, BMI, waist circumference, history of diabetes, systolic BP | Higher plasma Vitamin C, due to better diet quality, is inversely related to high BP | [149] |
| Iowa Women’s Health Study             | 1923 post-menopausal diabetic women from U.S. (55 to 69 years) | 82–679 mg/day                 | Not reported                      | Age, total energy intake, history of hypertension, BMI, waist-hip ratio, smoking status and amount smoked, alcohol consumption, physical activity score, hormone replacement therapy, main type and duration of diabetes, medications | After a follow-up of 11 years, an association between increased mortality for CVD or CHD and Vitamin C ≥ 300 mg/day was reported. Vitamin C intake was unrelated to CVD and stroke mortality in nondiabetic women. | [150] |
| Italian section of the EPIC Study     | 41,620 Italians previously diagnosed with stroke or myocardial infarction (44 to 61 years) | 83–201 mg/day                 | Not reported                      | Age, sex, hypertension, smoking, alcohol, education, energy intake, waist circumference, obesity, and physical activity | After 7.9 years of follow-up, Vitamin C was associated with a lower risk of ischemic stroke | [151] |
These findings were confirmed in 2004 in a pooled analysis of nine prospective cohort studies, showing that supplementation of vitamin C (≥700 mg/day) was inversely associated with CHD risk during a mean 10-year follow-up [152]. Conversely, in the same year, a prospective (15-year follow-up) cohort study (the Iowa Women’s Health Study Cohort) found a positive association between mortality for CHD and vitamin C supplementation (≥300 mg/day), assessed via food-frequency questionnaires in diabetic postmenopausal women [153].

In 2008, a meta-analysis based on 14 studies, for a total of 374,488 individuals with a median follow-up of ~10 years, concluded that dietary vitamin C has an inverse association with CHD risk, whereas supplement intake of vitamin C has no significant association with CHD risk [154]. Another large prospective cohort study conducted for a median follow-up of 16.5 years found an inverse association between dietary vitamin C intake determined by a food frequency questionnaire and CHD mortality in Japanese women without a history of CVD or cancer [155]. In 2013, a meta-analysis evaluating 15 trials for a total of 188,209 subjects found that vitamin C (in a range from 120 to 1000 mg) in association with vitamin E and beta-carotene had no significant effect on CHD and major cardiovascular events [156].

Taken together, these analyses indicate that the association between vitamin C intake and CHD risk remains controversial, with variable association depending on the source of vitamin C. It is important to emphasize at this point that the relationship between vitamin C intake and the actual vitamin C levels in the blood is not linear, hence it is not appropriate to extrapolate vitamin C levels from food intake questionnaires, and values ascertained via blood analyses are necessary [32,72].

The better accuracy of the quantification of vitamin C levels from blood samples compared to food frequency questionnaires is further confirmed when analyzing the outcomes of the European Investigation into Cancer and Nutrition (EPIC)–Norfolk study, a prospective study investigating the relationship between vitamin C and incident HF in 20,299 healthy adults. After a median follow-up of ~12.8 years, ascorbate was inversely associated with incident cases of HF; specifically, every 20 µmol/L increase in plasma vitamin C concentration was associated with a 9% reduced risk of HF [121,139]. Interestingly, in this study, dietary intake was the primary source of vitamin C as assessed by the food frequency questionnaire; however, the investigators did not find a significant association between the reported consumption of fruit and vegetables and lower risk of HF. Therefore, food questionnaires are inadequate to establish the exact vitamin C levels of an individual, hence it is reasonable to consider blood samples as a more reliable source [32,72].

In 2007, the clinical trial Women Antioxidant Cardiovascular Study tested the effects of vitamin C, alongside beta carotene and vitamin E, on the combined outcome of myocardial infarction, coronary revascularization, or cardiovascular death among 8171 female health professionals aged 40 years or older, with a history of CVD or at least three CVD risk factors, followed up for ~9.4 years; the study found no significant effects of ascorbic acid (500 mg/day) on cardiovascular events [143]. Similarly, the Physicians Health Study II (PHS II), a large trial conducted on 14,641 male subjects, including 754 men (5.1%) with prevalent CVD at randomization, revealed that vitamin C (500 mg/day) for ~8 years of follow-up had no significant effect on cardiovascular mortality [147]. In 2017, a meta-analysis of eight randomized controlled trials with a total of 15,445 participants, found inconsistent or low-quality (downgraded) evidence for a correlation between vitamin C supplementation and major cardiovascular events or cardiovascular mortality [157].

In light of the contradictory outcomes herein discussed, it appears that better quality studies are necessary to examine the effects of vitamin C on cardiovascular endpoints, particularly in participants with different risks of CVD. Furthermore, study participants should be tested to exclude the contribution from singular or multiple micronutrient deficiencies, since vitamin C deficiency is commonly accompanied by other micronutrient deficiencies and associated with other confounding aspects, including poor-quality diet [32,158].
| Meta-Analysis Topic | Number of Studies | Total Participants (n) | Trial Duration | Vitamin C Supplement Dosage | Outcome | Ref. |
|---------------------|-------------------|------------------------|----------------|-----------------------------|---------|------|
| Coronary Heart Disease | 14 cohorts | 374,488 | mean duration: 10 y. | Not reported | Dietary Vitamin C had an inverse association with CHD risk, but supplement intake of Vitamin C had no significant association with CHD risk. | [154] |
| Hypertension | 29 trials | 1407 | mean duration: 8 wks. | 60 to 4000 mg/day (median 500 mg/day) | Daily supplementation of Vitamin C in hypertensive participants reduced systolic BP by 3.84 mm Hg and DBP by 1.48 mm Hg. | [159] |
| Coronary Heart Disease | 15 trials | 188,209 | from 1.4 y. to 12 y. | 120 to 1000 mg/day | Vitamin C in association with Vitamin E and beta-carotene had no effect on CHD or other major cardiovascular events. Vitamin C in association with Vitamin E and beta-carotene had no effect on stroke risk compared to placebo. | [156] |
| Stroke | 16 cohorts | 217,454 participants for studies on Vitamin C intake 29,648 participants for studies on circulating Vitamin C | from 6.1 y. to 30 y. | 45 to 1167 mg/day | 19% lower risk of stroke (pooled analysis of 2 studies) comparing the highest to the lowest dietary Vitamin C intakes. 38% lower risk of stroke (pooled analysis of 6 studies) with the highest versus lowest circulating Vitamin C concentrations. | [160] |
| Endothelial function | 44 trials | 1324 | from 1 d. to 8 wks. | 500 to 2000 mg/day | A significant positive effect of Vitamin C supplementation on endothelial function measured by flow-mediated dilation (19 trials), evaluating pulse-wave (5 trials) and forearm blood flow (20 trials). | [161] |
Table 2. Cont.

| Meta-Analysis Topic                  | Number of Studies | Total Participants (n) | Trial Duration                   | Vitamin C Supplement Dosage | Outcome                                                                 | Ref.   |
|-------------------------------------|-------------------|------------------------|----------------------------------|-----------------------------|--------------------------------------------------------------------------|--------|
| Arterial stiffness                  | 22 trials         | 1909                   | from 1 d. to 7 y. (mean duration: 56 d.) | 120 to 4000 mg/day (mean 2000 mg/day) | Association of Vitamin C with Vitamin E and β-carotene improved arterial stiffness irrespective of the age group | [161]  |
| Cardiovascular events               | 8 trials          | 15,445                 | mean duration: 8 y.              | –                           | Inconsistent or low-quality (downgraded) evidence for the correlation between Vitamin C supplementation and major cardiovascular events or cardiovascular mortality | [157]  |
| Hypertension                        | 11 cross-sectional studies and 7 case-control studies | 22,200 | – | – | Serum Vitamin C level was significantly lower in hypertensive compared to normotensive subjects. Inverse correlation between serum Vitamin C concentration and SBP or DBP. | [162]  |
| Hypertension                        | 8 trials          | 614                    | from 4 wks. to 24 wks.           | 300 to 1000 mg/day          | Significantly reduced SBP and DBP in the subgroups of age ≥35 and ≥60 years with Vitamin C supplementation ≥500 mg/day for 6 weeks or more. | [163]  |
| Cardiovascular mortality            | 15 trials         | 320,548                | from 4 to 22y.                   | 50 to 450 mg/day            | Higher Vitamin C intake is associated with a lower risk of cardiovascular mortality | [164]  |
6. Vitamin C and Vascular Disease

We and others have shown that the endothelium plays a crucial role in the pathophysiology of vascular disorders [165–177]. Over the years, a significant number of clinical studies have investigated the effect of vitamin C on vascular disease, evidencing a promising association linking vitamin C intake, circulating levels of ascorbic acid, and lower risk of hypertension. Forman and coworkers reported data from three large prospective cohorts, namely the Nurses Health Study 1 (n = 88,540 women, median age 49 years), the Nurses Health Study 2 (n = 97,315 women, median age 36 years), and the Health Professionals Follow-up Study (n = 37,375 men, median age 52 years).

The risk of developing hypertension did not substantially change for individuals who had reported an intake upper or equal to 1500 mg/day of vitamin C compared to those with an intake lower than 250 mg/day [178].

However, when the vitamin C plasma concentration was directly measured, three independent cross-sectional studies indicated a significant inverse correlation between the concentrations of ascorbic acid and BP values [119,120,179]. Moran et al. reported that vitamin C plasma concentrations in a group of 168 healthy US citizen were inversely related to systolic BP (SBP) [119]. Myint et al. published their observations based on the EPIC-Norfolk cross-sectional study, showing a strong relationship between plasma vitamin C concentrations and lower clinic BP; after adjusting for confounders, the likelihood of having high BP was 22% lower for subjects in the top quartiles of plasma vitamin C levels compared to the bottom quartiles [120].

Block et al. examined in a cross-sectional analysis the association of plasma ascorbic acid with BP in a group of 242 women (aged 18–21 years), finding that plasma vitamin C was inversely associated with both SBP and diastolic BP (DBP), highlighting how persons in the highest quartile of the plasma ascorbic acid distribution had 4.66 mmHg lower systolic BP than those in the lowest quartile of the distribution [179].

These results are consistent with a meta-analysis of 29 trials for a total of 1407 participants including normotensive and hypertensive subjects, showing that daily supplementation with a range from 60 to 4000 mg of vitamin C (median dose: 500 mg) in hypertensive participants reduced systolic BP by 3.84 mm Hg and DBP by 1.48 mm Hg [159].

In 2015, the Coronary Artery Risk Development in Young Adults (CARDIA), a prospective cohort study collecting data from 2884 young adults initially hypertension free, revealed that higher plasma ascorbic acid can favorably influence BP [149]. A very recent meta-analysis, published in 2020 by Ran et al., selected 11 cross-sectional studies and 7 case-control studies conducted from 1990 to 2017; the authors reported that serum vitamin C levels in the study participants were significantly lower in hypertensive subjects than in normotensive ones; moreover, the authors found a significant reverse relationship between serum vitamin C concentration and both SBP and DBP [162].

In the same year, an independent meta-analysis published by Guan et al. supported the results of Ran’s study: The authors selected 8 randomized controlled trials in which vitamin C, varying from 300 to 1000 mg/day, was supplemented for 4–24 weeks to 614 hypertensive patients; the authors observed a marked reduction in DBP in the subgroup of patients with an age ≥35 years having a vitamin C supplementation ≥500 mg/day for 6 weeks, while a significant reduction of both SBP and DBP was observed in the subgroup of age ≥60 years [163].

Overall, these findings highlight how vitamin C is inversely associated with both SBP and DBP, indicating that people with hypertension could exhibit low serum vitamin C compared to normotensive subjects.

Bruno and colleagues demonstrated that acute vitamin C infusion (3 g i.v. in 5 min) significantly lowers BP in hypertensive patients but not in normotensive subjects; additionally, muscle sympathetic nerve activity was significantly reduced after vitamin C infusion in hypertensive patients but not in healthy subjects [180]. Corroborating these results, Heitzer et al. demonstrated that intra-arterial infusion of vitamin C (18 mg/min) had no significant effect on the forearm blood flow in response to acetylcholine (endothelium-dependent vasodilator) and sodium nitroprusside.
(endothelium-independent vasodilator) in 10 control subjects; however, in 10 chronic smokers, acetylcholine with the concomitant infusion of vitamin C markedly improved the impaired forearm blood flow responses [181]. Similarly, vitamin C supplementation (1000 mg for 4 weeks) significantly reduced LDL oxidative susceptibility in a group of smokers [182].

However, a subsequent clinical trial conducted on 34 male smokers did not support these observations; in fact, compared to placebo, supplementation of vitamin C (250 mg twice daily for 4 weeks) significantly increased plasma ascorbate concentrations but did not significantly change the levels of circulating oxidized LDL, nor of markers of endothelial activation like sICAM–1, sVCAM–1, and vWF-antigen [183].

In 2003, Salonen et al. published the results of the 6–year ASAP trial, in which slow-release vitamin C (250 mg) in addition to vitamin E (136 IU) were supplemented twice daily in hypercholesterolemic subjects [142]. Ultrasound assays proved that the vitamin C supplementation reduced the slope of the mean carotid artery intima-media thickness progression by 26%, with a significance that was reached in men (33% of reduction) but not in women (14% of reduction) [142]. These findings confirmed the observations previously obtained in the same ASAP trial at a shorter 3–year follow-up [184].

In 2014, two meta-analyses authored by Ashor and collaborators provided interesting findings concerning the link between vitamin C plasma levels and endothelial function, supporting the above-mentioned observations previously made by Heitzer [181] and Salonen [142]. The first meta-analysis, examining 44 randomized clinical trials comprising 1324 participants (964 males and 360 females) with a median age of ~51 years, revealed a significant positive effect of vitamin C supplementation (>500 mg/day) on endothelial function measured by flow-mediated dilation (19 studies) [161]. The action of vitamin C on endothelial function appeared to be dependent on health status, with stronger effects in atherosclerotic and diabetic patients. The second meta-analysis, performed on 22 randomized controlled trials, which included 1909 subjects (1088 males and 821 females) with an age that ranged from 22 to 63.5 (median of 29) years, reported that supplementation of vitamins C (120 to 4000 mg/day), E, A, and β–carotene improved arterial stiffness irrespective of the age group and duration of intervention [161]; notably, antioxidant vitamins were more effective in participants with low baseline plasma concentrations of vitamin C [161].

Recent trials have shown that Vitamin C ameliorates the oxidative imbalance and vascular remodeling induced by different stressors, including reperfusion injury following myocardial infarction [185], hyperoxya [186,187], shear stress [188], prolonged immobilization [189], glucose load [190], and mental stress [191,192]. Vitamin C also increases skeletal muscle blood flow and oxygen consumption via local vasodilation during exercise [193]. Vitamin C has also been shown to significantly attenuate endothelial barrier permeability [194–196], an aspect that has major implications in infectious disorders [197–200], which are also known to cause a systemic surge in oxidative stress [201–203].

Therefore, the antioxidant roles of Vitamin C and its protective effects on endothelial permeability could come into effect especially during infective processes [204–207]. Vitamin C has also been shown to improve the effects of other agents in a synergistic manner: for instance, when added to metformin, Vitamin C reduces cardiovascular diabetic complications [208], when added to glucagon-like peptide 1 (GLP–1), it further ameliorates endothelial function and reduces oxidative stress in Type 1 diabetic patients [209].

Thus, it is possible that the association of Vitamin C with other nutrients and micronutrients playing akin beneficial actions could be harnessed [210]. For instance, the supplementation of L-Arginine has been shown to play a favorable role in the regulation of immune responses [211,212]. Similarly, both Vitamin C and L-Arginine are known to improve endothelial function and reduce vascular permeability during infectious disorders [213–216]. Consequently, it is possible to speculate that their association could be synergistic in tackling infectious diseases; for instance, as COVID–19 is causing endotheliopathy [169], the association of oral L-arginine and liposomal vitamin C (e.g., Bioarginina® C, 2 vials/day) could be efficacious for COVID–19 and other infectious disorders.
Several studies have assessed the association between Vitamin C and the potential protection from cerebrovascular disease, and the results have been subject of much controversy, similarly to what observed in the investigations assessing CHD. A prospective cohort study that followed for 20 years the residents of a rural Japanese community, having an age of 40 years or older and initially free of stroke diagnosis, has shown that higher serum Vitamin C concentration was associated with a reduced risk of incidence of both hemorrhagic and ischemic stroke [217]. Only a small part of these associations could be explained by lowering BP and adjusting for the physical activity level [217]. Similarly, in 20,649 adults followed for 10 years in the prospective cohort study EPIC-Norfolk, plasma ascorbate concentrations in the top quartile were linked to a 42% lower risk of stroke compared to the values in the lowest quartile [140].

Of note, in both the EPIC-Norfolk [140] and Japanese [217] populations, blood Vitamin C concentrations were positively correlated with vegetable and fruit intake. In 2011 Del Rio and colleagues investigated the relationship between dietary total antioxidant capacity and the risk of hemorrhagic and ischemic stroke in 41,620 subjects not previously diagnosed with myocardial infarction or stroke, recruited from the Italian segment of the European Prospective Investigation into Cancer and Nutrition (EPIC) study; the results from specific sub-analyses on the different stroke types indicate that Vitamin C is associated with a decreased risk of ischemic stroke [151]. These studies were consistent with a meta-analysis published in 2013, in which 16 prospective studies reported a 19% lower risk of stroke (pooled analysis of 2 studies) when comparing the highest vs. the lowest dietary Vitamin C intake, and a 38% lower risk of stroke (pooled analysis of 6 studies) when comparing the highest vs. the lowest circulating Vitamin C concentration [160].

On the other hand, Sesso and collaborators reported the results of a randomized double-blind placebo-controlled trial conducted in 14,641 healthy US male physicians, enrolled in the PHS II study at ≥50 years of age, showing that Vitamin C supplementation (500 mg/day) had no significant effect on the mortality from, or the incidence of, any type of stroke after a mean follow-up of ~8 years [156]. In agreement with these observations, Ye and collaborators published a meta-analysis study of 15 trials for a total of 188,209 participants, reporting that the supplementation of Vitamin C (in a range from 120 to 1000 mg) in association with Vitamin E and beta-carotene, had no significant effects on the risk of stroke compared to placebo [156].

7. Conclusions

Both preclinical and clinical data available in the literature show that Vitamin C plays a pivotal role in a number of processes involved in the pathogenesis of CVD. Nevertheless, major limitations have to be taken in consideration when interpreting the results of the studies investigating the effects of Vitamin C on human health; for instance, dietary assessment methods such as questionnaires or food diaries lack precision and accuracy and do not embrace other conditions that can affect Vitamin C levels and homeostasis [35,218–222]; therefore, these approaches are inadequate to ascertain the accurate Vitamin C status of an individual. Henceforth, it is reasonable to consider blood samples as more reliable indicators. Equally important, plasma Vitamin C level may considerably fluctuate following food or supplement ingestion. Consequently, the most reliable and practically available information on Vitamin C status can only be obtained from blood samples withdrawn in fasted conditions [32,72]. Ascorbate is rapidly oxidized ex vivo and the resulting oxidation products are quickly metabolized or degraded [38], hence, in order to obtain valid and consistent Vitamin C concentrations, a scrupulous sample handling is essential. Furthermore, the use of liposomal Vitamin C should be preferred to other forms since liposomes might be an excellent carrier for Vitamin C to achieve high blood levels.

Therefore, further studies are needed to clarify whether Vitamin C supplementation is actually effective in the prevention or cure of CVD. Specifically, prospective randomized clinical trials in large populations are needed to better define the best dose, the ideal administration route, the optimal targets, as well as the contribution of dietary supplementation of other antioxidant elements; in order
to have standardized and reproducible data, it will be important to evaluate the Vitamin C status using blood samples obtained from fasted individuals.

**Author Contributions:** Data curation, writing—original draft preparation, M.B.M., J.G., V.C., and G.S.; writing—review and editing, M.B.M., J.G., V.T., and G.S.; supervision, G.S.; funding acquisition, G.S. and J.G. All authors have read and agreed to the published version of the manuscript.

**Funding:** The Santulli’s lab is supported in part by the NIH (R01–DK123259, R01–HL146691, R01–DK033823, R00–DK107895, R56–AG066431 to G.S.) and by the American Heart Association (AHA–20POST35211151 to J.G.).

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the paper.

**References**

1. Kyle, R.A.; Shampo, M.A. Albert Szent-Gyorgy—Nobel laureate. *Mayo Clin. Proc.* **2000**, *75*, 722. [CrossRef]
2. Szent-Gyorgyi, A. The Identification of Vitamin C. *Science* **1938**, *87*, 214–215. [CrossRef] [PubMed]
3. Zilva, S.S. The Antiscorbutic Fraction of Lemon Juice. I. *Biochem. J.* **1924**, *18*, 182–185. [CrossRef] [PubMed]
4. Carpenter, K.J. The discovery of vitamin C. *Ann. Nutr. Metab*. **2012**, *61*, 259–264. [CrossRef]
5. De Tullio, M.C. Beyond the antioxidant: The double life of vitamin C. *Subcell. Biochem.* **2012**, *56*, 49–65.
6. Frei, B.; England, L.; Ames, B.N. Ascorbate is an outstanding antioxidant in human blood plasma. *Proc. Natl. Acad. Sci. USA* **1989**, *86*, 6377–6381. [CrossRef]
7. Frei, B.; Stocker, R.; England, L.; Ames, B.N. Ascorbate: The most effective antioxidant in human blood plasma. *Adv. Exp. Med. Biol.* **1990**, *264*, 155–163.
8. Wyckelsma, V.L.; Venckunas, T.; Brazaitis, M.; Gastaldello, S.; Snieckus, A.; Eimantas, N.; Baranauskiene, N.; Subocius, A.; Skurvydas, A.; Paasuke, M.; et al. Vitamin C and E Treatment Blunts Sprint Interval Training-Induced Changes in Inflammatory Mediator-, Calcium-, and Mitochondria-Related Signaling in Recreationally Active Elderly Humans. *Antioxidants* **2020**, *9*, 879. [CrossRef]
9. Jacob, R.A.; Sotoudeh, G. Vitamin C function and status in chronic disease. *Nutr. Clin. Care* **2002**, *5*, 66–74. [CrossRef]
10. Van den Berg, J.J.; Kuypers, F.A.; Roelofsen, B.; den Kamp, J.A.O. The cooperative action of vitamins E and C in the protection against peroxidation of parinaric acid in human erythrocyte membranes. *Chem. Phys. Lipids* **1990**, *53*, 309–320. [CrossRef]
11. Johnston, C.S.; Meyer, C.G.; Srilakshmi, J.C. Vitamin C elevates red blood cell glutathione in healthy adults. *Am. J. Clin. Nutr.* **1993**, *58*, 103–105. [CrossRef] [PubMed]
12. Englard, S.; Seifter, S. The biochemical functions of ascorbic acid. *Annu. Rev. Nutr.* **1986**, *6*, 365–406. [CrossRef] [PubMed]
13. Li, Y.; Schellhorn, H.E. New developments and novel therapeutic perspectives for vitamin C. *J. Nutr.* **2007**, *137*, 2171–2184. [CrossRef] [PubMed]
14. Carr, A.C.; Frei, B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. *Am. J. Clin. Nutr.* **1999**, *69*, 1086–1107. [CrossRef]
15. Warner, M.J.; Kamran, M.T. *Anemia, Iron Deficiency*; StatPearls: Treasure Island, FL, USA, 2020.
16. Sourabh, S.; Bhatia, P.; Jain, R. Favourable improvement in haematological parameters in response to oral iron and vitamin C combination in children with Iron Refractory Iron Deficiency Anemia (IRIDA) phenotype. *Blood Cells Mol. Dis.* **2019**, *75*, 26–29. [CrossRef]
17. Hunt, J.R.; Gallagher, S.K.; Johnson, L.K. Effect of ascorbic acid on apparent iron absorption by women with low iron stores. *Am. J. Clin. Nutr.* **1994**, *59*, 1381–1385. [CrossRef]
18. Davidsson, L.; Galan, P.; Kastenmayer, P.; Cherouvrier, F.; Juillerat, M.A.; Hercberg, S.; Hurrell, R.F. Iron bioavailability studied in infants: The influence of phytic acid and ascorbic acid in infant formulas based on soy isolate. *Pediatr. Res.* **1994**, *36*, 816–822. [CrossRef]
19. Linster, C.L.; Van Schaftingen, E. Vitamin C. Biosynthesis, recycling and degradation in mammals. *FEBS J.* **2007**, *274*, 1–22. [CrossRef]
20. Drouin, G.; Godin, J.R.; Page, B. The genetics of vitamin C loss in vertebrates. *Curr. Genom.* **2011**, *12*, 371–378. [CrossRef]
21. Grollman, A.P.; Lehninger, A.L. Enzymic synthesis of L-ascorbic acid in different animal species. *Arch. Biochem. Biophys.* 1957, 69, 458–467. [CrossRef]

22. Bublitz, C.; Lehninger, A.L. The enzymic conversion of L-gulonate to L-ascorbate by rat-liver enzymes. *Biochim. Biophys. Acta* 1959, 32, 290–291. [CrossRef]

23. Chatterjee, I.B.; Chatterjee, G.C.; Ghosh, N.C.; Ghosh, J.J.; Guha, B.C. Biological synthesis of L-ascorbic acid in animal tissues: Conversion of L-gulonolactone into L-ascorbic acid. *Biochem. J.* 1960, 74, 193–203. [CrossRef] [PubMed]

24. Nishikimi, M.; Yagi, K. Molecular basis for the deficiency in humans of gulonolactone oxidase, a key enzyme for ascorbic acid biosynthesis. *Am. J. Clin. Nutr.* 1991, 54, 1203S–1208S. [CrossRef] [PubMed]

25. Nishikimi, M.; Kawai, T.; Yagi, K. Guinea pigs possess a highly mutated gene for L-gulono-gamma-lactone oxidase, the key enzyme for L-ascorbic acid biosynthesis missing in this species. *J. Biol. Chem.* 1992, 267, 21967–21972.

26. Pollock, J.I.; Mullin, R.J. Vitamin C biosynthesis in prosimians: Evidence for the anthropoid affinity of *Tarsius*. *Am. J. Phys. Anthropol.* 1987, 73, 65–70. [CrossRef]

27. Birney, E.C.; Jenness, R.; Ayaz, K.M. Inability of bats to synthesise L-ascorbic acid. *Nature* 1976, 260, 626–628. [CrossRef]

28. Milton, K.; Jenness, R. Ascorbic acid content of neotropical plant parts available to wild monkeys and bats. *Experientia* 1987, 43, 339–342. [CrossRef]

29. Institute of Medicine (US). *Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids*; National Academies Press: Washington, DC, USA, 2000.

30. Hampl, J.S.; Taylor, C.A.; Johnston, C.S. Vitamin C deficiency and depletion in the United States: The Third National Health and Nutrition Examination Survey, 1988 to 1994. *Am. J. Public Health* 2004, 94, 870–875. [CrossRef]

31. Schleicher, R.L.; Carroll, M.D.; Ford, E.S.; Lacher, D.A. Serum vitamin C and the prevalence of vitamin C deficiency in the United States: 2003–2004 National Health and Nutrition Examination Survey (NHANES). *Am. J. Clin. Nutr.* 2009, 90, 1252–1263. [CrossRef]

32. Rowe, S.; Carr, A.C. Global Vitamin C Status and Prevalence of Deficiency: A Cause for Concern? *Nutrients* 2020, 12, 2008. [CrossRef]

33. Villalpando, S.; Montalvo-Velarde, I.; Zambrano, N.; Garcia-Guerra, A.; Ramirez-Silva, C.I.; Shamah-Levy, T.; Rivera, J.A. Vitamins A, and C and folate status in Mexican children under 12 years and women 12–49 years: A probabilistic national survey. *Salud Publica Mex* 2003, 45, S508–S519. [CrossRef] [PubMed]

34. Garcia, O.P.; Ronquillo, D.; Mdel, C.C.; Camacho, M.; Long, K.Z.; Rosado, J.L. Zinc, vitamin A, and vitamin C status are associated with leptin concentrations and obesity in Mexican women: Results from a cross-sectional study. *Nutr. Metab.* 2012, 9, 59. [CrossRef] [PubMed]

35. Cahill, L.; Corey, P.N.; El-Sohemy, A. Vitamin C deficiency in a population of young Canadian adults. *Am. J. Epidemiol.* 2009, 170, 464–471. [CrossRef] [PubMed]

36. Dewhirst, R.A.; Fry, S.C. The oxidation of dehydroascorbic acid and 2,3-diketogulonate by distinct reactive oxygen species. *Biochem. J.* 2018, 475, 3451–3470. [CrossRef]

37. Sauberlich, H.E. Pharmacology of vitamin C. *Annu. Rev. Nutr.* 1994, 14, 371–391. [CrossRef]

38. Arrigoni, O.; De Tullio, M.C. Ascorbic acid: Much more than just an antioxidant. *Biochim. Biophys. Acta* 2002, 1569, 1–9. [CrossRef]

39. Rose, R.C. Solubility properties of reduced and oxidized ascorbate as determinants of membrane permeation. *Biochim. Biophys. Acta* 1987, 924, 254–256. [CrossRef]

40. Zhitkovich, A. Nuclear and Cytoplasmic Functions of Vitamin C. *Chem. Res. Toxicol.* 2020, 33, 2515–2526. [CrossRef] [PubMed]
45. Tsukaguchi, H.; Tokui, T.; Mackenzie, B.; Berger, U.V.; Chen, X.Z.; Wang, Y.; Brubaker, R.F.; Hediger, M.A. A family of mammalian Na+-dependent L-ascorbic acid transporters. *Nature* 1999, 399, 70–75. [CrossRef] [PubMed]

46. Sotiriou, S.; Gispert, S.; Cheng, J.; Wang, Y.; Chen, A.; Hoogstraten-Miller, S.; Miller, G.F.; Kwon, O.; Levine, M.; Gutten tag, S.H.; et al. Ascorbic-acid transporter Scl23a1 is essential for vitamin C transport into the brain and for perinatal survival. *Nat. Med.* 2002, 8, 514–517. [CrossRef] [PubMed]

47. Subramanian, V.S.; Srinivasan, P.; Wildman, A.J.; Marchant, J.S.; Said, H.M. Molecular mechanism(s) involved in differential expression of vitamin C transporters along the intestinal tract. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2017, 312, G340–G347. [CrossRef] [PubMed]

48. Macias, R.I.; Hierro, C.; de Juan, S.C.; Jimenez, F.; Martin, F.G.-S.; Marin, J.J. Hepatic expression of 

49. Larsson, N.; Rankin, G.D.; Bicer, E.M.; Roos-Engstrand, E.; Pourazar, J.; Blomberg, A.; Mudway, I.S.; Wang, Y.; Mackenzie, B.; Tsukaguchi, H.; Weremowicz, S.; Morton, C.C.; Hediger, M.A. Human vitamin C 

50. Portugal, C.C.; Socodato, R.; Canedo, T.; Silva, C.M.; Martins, T.; Coreixas, V.S.; Loiola, E.C.; Gess, B.; Rohr, D.; Santiago, A.R.; et al. Caveolin-1-mediated internalization of the vitamin C transporter SVCT2 in microglia triggers an inflammatory phenotype. *Sci. Signal.* 2017, 10. [CrossRef]

51. Santulli, G. Adrenal Glands: From Pathophysiology to Clinical Evidence; Nova Science Publishers, Inc.: Hauppauge, NY, USA, 2015.

52. Portugal, C.C.; da Encarnacao, T.G.; Socodato, R.; Moreira, S.R.; Brudzewsky, D.; Ambrosio, A.F.; Paes-de-Carvalho, R. Nitric oxide modulates sodium vitamin C transporter 2 (SVCT-2) protein expression via protein kinase G (PKG) and nuclear factor-kappaB (NF-kappaB). *J. Biol. Chem.* 2012, 303, C645–C653. [CrossRef]

53. Ludke, A.R.; Sharma, A.K.; Akolkar, G.; Baijai, G.; Singal, P.K. Downregulation of vitamin C transporter SVCT-2 in doxorubicin-induced cardiomyocyte injury. *Am. J. Physiol. Cell Physiol.* 2012, 303, 876–887. [CrossRef] [PubMed]

54. Portugal, C.C.; da Encarnacao, T.G.; Socodato, R.; Moreira, S.R.; Brudzewsky, D.; Ambrosio, A.F.; Paes-de-Carvalho, R. Nitric oxide modulates vitamin C transport in adult human small intestinal brush border membrane vesicles. *J. Nutr.* 2000, 130, 63–69. [CrossRef] [PubMed]

55. Cho, S.; Chae, J.S.; Shin, H.; Shin, Y.; Song, H.; Kim, Y.; Yoo, B.C.; Roh, K.; Cho, S.; Kil, E.J.; et al. Hormetic dose response to L-ascorbic acid as an anti-cancer drug in colorectal cancer cell lines according to SVCT-2 expression. *Sci. Rep.* 2018, 8, 13172. [CrossRef] [PubMed]

56. Malo, C.; Wilson, J.X. Glucose modulates vitamin C transport in adult human small intestinal brush border vesicles. *J. Nutr.* 2000, 130, 63–69. [CrossRef] [PubMed]

57. Nualart, F.; Mack, L.; Garcia, A.; Cisternas, P.; Bongarzone, E.R.; Heitzer, M.; Jara, N.; Martinez, F.; Ferrada, L.; Espinoza, F.; et al. Vitamin C Transporters, Recycling and the Bystander Effect in the Nervous System: SVCT2 versus Gluts. *J. Stem. Cell Res. Ther.* 2014, 4, 209. [CrossRef]

58. Vera, J.C.; Rivas, C.I.; Fischbarg, J.; Golde, D.W. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. *Nature* 1993, 364, 79–82. [CrossRef]

59. Corpe, C.P.; Eck, P.; Wang, J.; Al-Hasani, H.; Levine, M. Intestinal dehydroascorbic acid (DHA) transport mediated by the facilitative sugar transporters, GLUT2 and GLUT8. *J. Biol. Chem.* 2013, 288, 9092–9101. [CrossRef]

60. Dong, W.; Tian, C.; Jiao, Y.; Blackwell, S.; Lou, G.; Postlethwaite, A.; Gu, W.; Sun, D. Multiple genome analyses reveal key genes in Vitamin C and Vitamin D synthesis and transport pathways are shared. *Sci. Rep.* 2019, 9, 16811. [CrossRef]

61. Lukawski, M.; Dalek, P.; Witkiewicz, W.; Przybylo, M.; Langner, M. Experimental evidence and physiological significance of the ascorbate passive diffusion through the lipid bilayer. *Chem. Phys. Lipids* 2020, 232, 104950. [CrossRef]

62. Pozzer, D.; Invernizzi, R.W.; Blaauw, B.; Cantoni, O.; Zito, E. Ascorbic Acid Route to the Endoplasmic Reticulum: Function and Role in Disease. *Antioxid. Redox Signal.* 2020. [CrossRef]

63. Nygaard, G. On a Novel, Simplified Model Framework Describing Ascorbic Acid Concentration Dynamics. *Annu. Int. Conf. IEEE Eng. Med. Biol. Soc.* 2019, 2019, 2880–2886.
64. Bozonet, S.M.; Carr, A.C. The Role of Physiological Vitamin C Concentrations on Key Functions of Neutrophils Isolated from Healthy Individuals. *Nutrients* 2019, 11, 1363. [CrossRef] [PubMed]

65. Corpe, C.P.; Tu, H.; Eck, P.; Wang, J.; Faulhaber-Walter, R.; Schnerrmann, J.; Margolis, S.; Padayatty, S.; Sun, H.; Wang, Y.; et al. Vitamin C transporter Slc23a1 links renal reabsorption, vitamin C tissue accumulation, and perinatal survival in mice. *J. Clin. Investig.* 2010, 120, 1069–1083. [CrossRef] [PubMed]

66. Levine, M.; Padayatty, S.J.; Espey, M.G. Vitamin C: A concentration-function approach yields pharmacology and therapeutic discoveries. *Adv. Nutr.* 2011, 2, 78–88. [CrossRef] [PubMed]

67. Levine, M.; Conry-Cantilena, C.; Wang, Y.; Welch, R.W.; Washko, P.W.; Dhariwal, K.R.; Park, J.B.; Lazarev, A.; Graumlich, J.F.; King, J.; et al. Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance. *Proc. Natl. Acad. Sci. USA* 1996, 93, 3704–3709. [CrossRef] [PubMed]

68. Padayatty, S.J.; Sun, H.; Wang, Y.; Riordan, H.D.; Hewitt, S.M.; Katz, A.; Wesely, R.A.; Levine, M. Vitamin C pharmacokinetics: Implications for oral and intravenous use. *Ann. Intern. Med.* 2004, 140, 533–537. [CrossRef] [PubMed]

69. Mackenzie, B.; Illing, A.C.; Hediger, M.A. Transport model of the human Na+-coupled L-ascorbic acid (vitamin C) transporter SVCT1. *Am. J. Physiol. Cell Physiol.* 2008, 294, C451–C459. [CrossRef] [PubMed]

70. Wohlrab, C.; Phillips, E.; Dachs, G.U. Vitamin C Transporters in Cancer: Current Understanding and Gaps in Knowledge. *Front. Oncol.* 2017, 7, 74. [CrossRef]

71. Roa, F.J.; Pena, E.; Inostroza, E.; Sotomayor, K.; Gonzalez, M.; Gutierrez-Castro, F.A.; Maurin, M.; Sweet, K.; Labrousse, C.; Gatica, M.; et al. Data on SVCT2 transporter expression and localization in cancer cell lines and tissues. *Data Br.* 2019, 25, 103972. [CrossRef]

72. Lykkesfeldt, J. On the effect of vitamin C intake on human health: How to (mis)interpret the clinical evidence. *Redox Biol.* 2020, 34, 101532. [CrossRef]

73. Wilson, J.X. Regulation of vitamin C transport. *Annu. Rev. Nutr.* 2005, 25, 105–125. [CrossRef]

74. Stephenson, C.M.; Levin, R.D.; Spector, T.; Lis, C.G. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. *Cancer Chemother. Pharmacol.* 2013, 72, 139–146. [CrossRef] [PubMed]

75. Bangham, A.D.; Horne, R.W. Negative Staining of Phospholipids and Their Structural Modification by Surface-Active Agents as Observed in the Electron Microscope. *J. Mol. Biol.* 1964, 8, 660–668. [CrossRef]

76. Yao, X.; Fan, X.; Yan, N. Cryo-EM analysis of a membrane protein embedded in the liposome. *Proc. Natl. Acad. Sci. USA* 2020, 117, 18497–18503. [CrossRef] [PubMed]

77. Deamer, D.W. From “banghasomes” to liposomes: A memoir of Alec Bangham, 1921–2010. *FASEB J.* 2010, 24, 1308–1310. [CrossRef] [PubMed]

78. Mozafari, M.R. Liposomes: An overview of manufacturing techniques. *Cell. Mol. Biol. Lett.* 2005, 10, 711–719. [PubMed]

79. Madni, A.; Sarfraz, M.; Rehman, M.; Ahmad, M.; Akhtar, N.; Ahmad, S.; Tahir, N.; Ijaz, S.; Al-Kassas, R.; Lobenberg, R. Liposomal drug delivery: A versatile platform for challenging clinical applications. *J. Pharm. Pharmc Sci.* 2014, 17, 401–426. [CrossRef]

80. Karn, P.R.; Cho, W.; Hwang, S.J. Liposomal drug products and recent advances in the synthesis of supercritical fluid-mediated liposomes. *Nanomedicine* 2013, 8, 1529–1548. [CrossRef]

81. Nayerhoda, R.; Hill, A.; Pfeifer, B.A. Liposomal Dual Delivery of Both Polysaccharide and Protein Antigens. *Methods Mol. Biol.* 2021, 2183, 477–487.

82. Bozzuto, G.; Molinari, A. Liposomes as nanomedical devices. *Int. J. Nanomed.* 2015, 10, 975–999. [CrossRef]

83. Kauffman, K.J.; Dorkin, J.R.; Yang, J.H.; Heartlein, M.W.; DeRosa, F.; Mir, F.F.; Fenton, O.S.; Anderson, D.G. Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. *Nano Lett.* 2015, 15, 7300–7306. [CrossRef]

84. Kamaly, N.; Miller, A.D. Paramagnetic liposome nanoparticles for cellular and tumour imaging. *Int. J. Mol. Sci.* 2010, 11, 1759–1776. [CrossRef] [PubMed]

85. Lee, J.H.; Shin, Y.; Lee, W.; Whang, K.; Kim, D.; Lee, L.P.; Choi, J.W.; Kang, T. General and programmable synthesis of hybrid liposome/metal nanoparticles. *Sci. Adv.* 2016, 2, e1601838. [CrossRef] [PubMed]

86. Yang, S.; Liu, C.; Liu, W.; Yu, H.; Zheng, H.; Zhou, W.; Hu, Y. Preparation and characterization of nanoliposomes entrapping medium-chain fatty acids and vitamin C by lyophilization. *Int. J. Mol. Sci.* 2013, 14, 19763–19773. [CrossRef] [PubMed]
87. Moribe, K.; Limwikrant, W.; Higashi, K.; Yamamoto, K. Drug nanoparticle formulation using ascorbic Acid derivatives. J. Drug. Deliv. 2011, 2011, 138929. [CrossRef] [PubMed]
88. Preiss, M.R.; Bothun, G.D. Stimuli-responsive liposome-nanoparticle assemblies. Expert Opin. Drug Deliv. 2011, 8, 1025–1040. [CrossRef]
89. Ross, C.; Taylor, M.; Fullwood, N.; Allsop, D. Liposome delivery systems for the treatment of Alzheimer’s disease. Int. J. Nanomed. 2018, 13, 8507–8522. [CrossRef]
90. Ickenstein, L.M.; Garidel, P. Lipid-based nanoparticle formulations for small molecules and RNA drugs. Expert Opin. Drug Deliv. 2019, 16, 1205–1226. [CrossRef]
91. Selecì, M.; Selecì, D.A.; Scheper, T.; Stahl, F. Theranostic Liposome-Nanoparticle Hybrids for Drug Delivery and Bioimaging. Int. J. Mol. Sci. 2017, 18, 1415. [CrossRef]
92. Zylberberg, C.; Gaskill, K.; Pasley, S.; Matosevic, S. Engineering liposomal nanoparticles for targeted gene therapy. Gene Ther. 2017, 24, 441–452. [CrossRef]
93. Michel, R.; Gradzielski, M. Experimental aspects of colloidal interactions in mixed systems of liposome and inorganic nanoparticle and their applications. Int. J. Mol. Sci. 2012, 13, 11610–11642. [CrossRef]
94. Zamani, P.; Montaz-Borjomi, A.A.; Nik, M.E.; Oskuee, R.K.; Salehkar, A. Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy. J. Cell. Physiol. 2018, 233, 5189–5199. [CrossRef] [PubMed]
95. Cheng, W.; Compton, R.G. Investigation of single-drug-encapsulating liposomes using the nano-impact method. Angew. Chem. Int. Ed. Engl. 2014, 53, 13928–13930. [CrossRef] [PubMed]
96. Kobayashi, K.; Seike, Y.; Saeki, A.; Kozawa, T.; Takeuchi, F.; Tsubaki, M. A pulse radiolysis study of the dynamics of ascorbic acid free radicals within a liposomal environment. ChemPhysChem 2014, 15, 2994–2997. [CrossRef] [PubMed]
97. Venaja, K.; Wahl, M.A.; Bukarica, L.; Heinle, H. Liposomes as carriers of the lipid soluble antioxidant resveratrol: Evaluation of amelioration of oxidative stress by additional antioxidant vitamin. Life Sci. 2013, 93, 917–923. [CrossRef] [PubMed]
98. Chen, Y.; Song, W.; Shen, L.; Qiu, N.; Hu, M.; Liu, Y.; Liu, Q.; Huang, L. Vasodilator Hydralazine Promotes Nanoparticle Penetration in Advanced Desmoplastic Tumors. ACS Nano 2019, 13, 1751–1763. [CrossRef] [PubMed]
99. Attia, M.; Essa, E.A.; Zaki, R.M.; Elkordy, A.A. An Overview of the Antioxidant Effects of Ascorbic Acid and Alpha Lipoic Acid (in Liposomal Forms) as Adjuvant in Cancer Treatment. Antioxidants 2020, 9, 359. [CrossRef] [PubMed]
100. Felice, B.; Prabhakaran, M.P.; Rodriguez, A.P.; Ramakrishna, S. Drug delivery vehicles on a nano-engineering perspective. Mater. Sci. Eng. C Mater. Biol. Appl. 2014, 41, 178–195. [CrossRef]
101. Tavano, L.; Muzzalupo, R.; Picci, N.; de Cindio, B. Co-encapsulation of antioxidants into niosomal carriers: One compound, several uses. Advances for delivery, efficiency and stability. Nanomedicine 2020, 24, 102117. [CrossRef] [PubMed]
108. Lukawski, M.; Dalek, P.; Borowik, T.; Forys, A.; Langner, M.; Witkiewicz, W.; Przybylo, M. New oral liposomal vitamin C formulation: Properties and bioavailability. *J. Liposome Res.* **2020**, *30*, 227–234. [CrossRef] [PubMed]

109. Maione-Silva, L.; de Castro, E.G.; Nascimento, T.L.; Cintra, E.R.; Moreira, L.C.; Cintra, B.A.S.; Valadares, M.C.; Lima, E.M. Ascorbic acid encapsulated into negatively charged liposomes exhibits increased skin permeation, retention and enhances collagen synthesis by fibroblasts. *Sci. Rep.* **2019**, *9*, 522. [CrossRef] [PubMed]

110. Xiao, W.; Fu, Q.; Zhao, Y.; Zhang, L.; Yue, Q.; Hai, L.; Guo, L.; Wu, Y. Ascorbic acid-modified brain-specific liposomes drug delivery system with “lock-in” function. *Chem. Phys. Lipids* **2019**, *224*, 104727. [CrossRef] [PubMed]

111. Parhizkar, E.; Rashedinia, M.; Karimi, M.; Alipour, S. Design and development of vitamin C-encapsulated proliposome with improved in-vitro and ex-vivo antioxidant efficacy. *J. Microencapsul.* **2018**, *35*, 301–311. [CrossRef]

112. Jiao, Z.; Wang, X.; Yin, Y.; Xia, J.; Mei, Y. Preparation and evaluation of a chitosan-coated antioxidant liposome containing vitamin C and folic acid. *J. Microencapsul.* **2018**, *35*, 272–280. [CrossRef]

113. Miura, Y.; Fuchigami, Y.; Hagimori, M.; Sato, H.; Ogawa, K.; Munakata, C.; Wada, M.; Maruyama, K.; Kawakami, S. Evaluation of the targeted delivery of 5-fluorouracil and ascorbic acid into the brain with ultrasound-responsive nanobubbles. *J. Drug Target* **2018**, *26*, 684–691. [CrossRef]

114. Tsai, W.C.; Rizvi, S.S.H. Simultaneous microencapsulation of hydrophilic and lipophilic bioactives in biofabricated hydrogels. *J. Biomed. Mater. Eng.* **2020**, *30*, 41–50. [CrossRef]

115. Duong, J.; Miranda-Massari, J.R.; Gonzalez, M.J.; Jackson, J.A.; Warnock, W.; Riordan, N.H. Pharmacokinetics of vitamin C: Insights into the oral and intravenous administration of ascorbate. *P. R. Health Sci. J.* **2008**, *27*, 7–19. [PubMed]

116. Davis, J.L.; Paris, H.L.; Beals, J.W.; Binns, S.E.; Giordano, G.R.; Scalzo, R.L.; Schweder, M.M.; Blair, E.; Bell, C. Liposomal-encapsulated Ascorbic Acid: Influence on Vitamin C Bioavailability and Capacity to Protect Against Ischemia-Reperfusion Injury. *Nutr. Metab. Insights* **2016**, *9*, 25–30. [CrossRef] [PubMed]

117. Gopi, S.; Balakrishnan, P. Evaluation and Clinical Comparison Studies on Liposomal and Non-Liposomal Ascorbic Acid (Vitamin C) and their Enhanced Bioavailability. *J. Liposome Res.* **2020**, 1–35. [CrossRef]

118. Ashor, A.W.; Siervo, M.; Lara, J.; Ogioni, C.; Mathers, J.C. Antioxidant vitamin supplementation reduces arterial stiffness in adults: A systematic review and meta-analysis of randomized controlled trials. *J. Nutr.* **2014**, *144*, 1594–1602. [CrossRef]

119. Moran, J.P.; Cohen, L.; Greene, J.M.; Xu, G.; Feldman, E.B.; Hames, C.G.; Feldman, D.S. Plasma ascorbic acid concentrations relate inversely to blood pressure in human subjects. *Am. J. Clin. Nutr.* **1993**, *57*, 213–217. [CrossRef]

120. Myint, P.K.; Luben, R.N.; Wareham, N.J.; Khaw, K.T. Association between plasma vitamin C concentrations and blood pressure in the European prospective investigation into cancer-Norfolk population-based study. *Hypertension* **2011**, *58*, 372–379. [CrossRef]

121. Pfister, R.; Sharp, S.J.; Luben, R.; Wareham, N.J.; Khaw, K.T. Plasma vitamin C predicts incident heart failure in men and women in European Prospective Investigation into Cancer and Nutrition-Norfolk prospective study. *Am. Heart J.* **2011**, *162*, 246–253. [CrossRef]

122. Heller, R.; Munschier-Paulig, F.; Grabner, R.; Till, U. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. *J. Biol. Chem.* **1999**, *274*, 8254–8260. [CrossRef]

123. Huang, A.; Vita, J.A.; Venema, R.C.; Keaney, J.F., Jr. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. *J. Biol. Chem.* **2000**, *275*, 17399–17406. [CrossRef]

124. Baker, T.A.; Milstien, S.; Katusic, Z.S. Effect of vitamin C on the availability of tetrahydrobiopterin in human endothelial cells. *J. Cardiovasc. Pharmacol.* **2001**, *37*, 333–338. [CrossRef] [PubMed]

125. D’Uscio, L.V.; Milstien, S.; Richardson, D.; Smith, L.; Katusic, Z.S. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. *Circ. Res.* **2003**, *92*, 88–95. [CrossRef] [PubMed]

126. Yan, J.; Tie, G.; Messina, L.M. Tetrahydrobiopterin, L-arginine and vitamin C acts synergistically to decrease oxidative stress, increase nitricoxide and improve blood flow after induction of hindlimb ischemia in the rat. *Mol. Med.* **2012**, *18*, 676–684. [CrossRef] [PubMed]

127. Ulker, S.; McKeown, P.P.; Bayraktutan, U. Vitamins reverse endothelial dysfunction through regulation of eNOS and NAD(P)H oxidase activities. *Hypertension* **2003**, *41*, 534–539. [CrossRef]
Antioxidants 2020, 9, 1227

128. Ladurner, A.; Schmitt, C.A.; Schachner, D.; Atanasov, A.G.; Werner, E.R.; Dirsch, V.M.; Heiss, E.H. Ascorbate stimulates endothelial nitric oxide synthase enzyme activity by rapid modulation of its phosphorylation status. Free Radic. Biol. Med. 2012, 52, 2082–2090. [CrossRef]

129. Yuan, Q.; Yang, J.; Santulli, G.; Reiken, S.R.; Wronskas, A.; Kim, M.M.; Osborne, B.W.; Lacampagne, A.; Yin, Y.; Marks, A.R. Maintenance of normal blood pressure is dependent on IP3R1-mediated regulation of eNOS. Proc. Natl. Acad. Sci. USA 2016, 113, 8532–8537. [CrossRef]

130. Forman, H.J.; Zhang, H.; Rinna, A. Glutathione: Overview of its protective roles, measurement, and biosynthesis. Mol. Asp. Med. 2009, 30, 1–12. [CrossRef]

131. Lushchak, V.I. Glutathione homeostasis and functions: Potential targets for medical interventions. J. Amino Acids 2012, 2012, 736837. [CrossRef]

132. Martensson, J.; Han, J.; Griffith, O.W.; Meister, A. Glutathione ester delays the onset of scurvy in ascorbate-deficient guinea pigs. Proc. Natl. Acad. Sci. USA 1993, 90, 317–321. [CrossRef]

133. Guaiquil, V.H.; Vera, J.C.; Golde, D.W. Mechanism of vitamin C inhibition of cell death induced by oxidative stress in glutathione-depleted HL-60 cells. J. Biol. Chem. 2001, 276, 40955–40961. [CrossRef]

134. Shang, F.; Lu, M.; Dudek, E.; Reddan, J.; Taylor, A. Vitamin C and vitamin E restore the resistance of GSH-depleted lens cells to H2O2. Free Radic. Biol. Med. 2003, 34, 521–530. [CrossRef]

135. Waly, M.I.; Al-Attabi, Z.; Guizani, N. Low Nourishment of Vitamin C Induces Glutathione Depletion and Oxidative Stress in Healthy Young Adults. Prev. Nutr. Food Sci. 2015, 20, 198–203. [CrossRef] [PubMed]

136. Brown, D.A.; Aon, M.A.; Frasier, C.R.; Sloan, R.C.; Maloney, A.H.; Anderson, E.J.; O'Rourke, B. Cardiac arrhythmias induced by glutathione oxidation can be inhibited by preventing mitochondrial depolarization. J. Mol. Cell. Cardiol. 2010, 48, 673–679. [CrossRef] [PubMed]

137. Rimm, E.B.; Stampfer, M.J.; Ascherio, A.; Giovannucci, E.; Colditz, G.A.; Willett, W.C. Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. 1993, 328, 1450–1456. [CrossRef]

138. Osogian, S.K.; Stampfer, M.J.; Rimm, E.; Spiegelman, D.; Hu, F.B.; Manson, J.E.; Willett, W.C. Vitamin C and risk of coronary heart disease in women. J. Am. Coll. Cardiol. 2003, 42, 246–252. [CrossRef]

139. Knekt, P.; Ritz, J.; Pereira, M.A.; O’Reilly, E.J.; Augustsson, K.; Fraser, G.E.; Goldbourt, U.; Heitmann, B.L.; Hallmans, G.; Liu, S.; et al. Antioxidant vitamins and coronary heart disease risk: A pooled analysis of 9 cohorts. Am. J. Clin. Nutr. 2004, 80, 1508–1520. [CrossRef]

140. Lee, D.H.; Folsom, A.R.; Harnack, L.; Halliwell, B.; Jacobs, D.R., Jr. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am. J. Clin. Nutr. 2004, 80, 1194–1200. [CrossRef]

141. Khaw, K.T.; Bingham, S.; Welch, A.; Luben, R.; Wareham, N.; Oakes, S.; Day, N. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: A prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet 2001, 357, 657–663. [CrossRef]

142. Myint, P.K.; Luben, R.N.; Welch, A.A.; Bingham, S.A.; Wareham, N.J.; Khaw, K.T. Plasma vitamin C concentrations predict risk of incident stroke over 10 y in 20 649 participants of the European Prospective Investigation into Cancer Norfolk prospective population study. Am. J. Clin. Nutr. 2008, 87, 64–69. [CrossRef]

143. Ascherio, A.; Rimm, E.B.; Hernan, M.A.; Giovannucci, E.; Kawachi, I.; Stampfer, M.J.; Willett, W.C. Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States. Ann. Intern. Med. 1999, 130, 963–970. [CrossRef]

144. Salonen, R.M.; Nyyssonen, K.; Kaikkonen, J.; Porkkala-Sarataho, E.; Voutilainen, S.; Rissanen, T.H.; Tuomainen, T.P.; Valkonen, V.P.; Ristomaa, U.; Aromaa, A.; et al. Antioxidant Supplementation in Atherosclerosis Prevention Study: Six-year effects of combined vitamin C and E supplementation on atherosclerotic progression. The Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 2003, 107, 947–953. [CrossRef] [PubMed]

145. Cook, N.R.; Albert, C.M.; Gaziano, J.M.; Zaharris, E.; MacFadyen, J.; Robinson, E.; Buring, J.E.; Manson, J.E. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: Results from the Women’s Antioxidant Cardiovascular Study. Arch. Intern. Med. 2007, 167, 1610–1618. [CrossRef] [PubMed]

146. Simon, J.A.; Hudes, E.S.; Tice, J.A. Relation of serum ascorbic acid to mortality among US adults. J. Am. Coll. Nutr. 2001, 20, 255–263. [CrossRef] [PubMed]

147. Simon, J.A.; Hudes, E.S.; Browner, W.S. Serum ascorbic acid and cardiovascular disease prevalence in U.S. adults. Epidemiology 1998, 9, 316–321. [CrossRef] [PubMed]
148. Hercberg, S.; Galan, P.; Preziosi, P.; Bertrais, S.; Mennen, L.; Malvy, D.; Roussel, A.M.; Favier, A.; Briancon, S. The SU.VI.MAX Study: A randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. *Arch. Intern. Med.* 2004, 164, 2335–2342. [CrossRef]

149. Sesso, H.D.; Buring, J.E.; Christen, W.G.; Kurth, T.; Belanger, C.; MacFadyen, J.; Bubes, V.; Hanson, J.E.; Glynn, R.J.; Gaziano, J.M. Vitamins E and C in the prevention of cardiovascular disease in men: The Physicians’ Health Study II randomized controlled trial. *JAMA* 2008, 300, 2123–2133. [CrossRef] [PubMed]

150. Heart Protection Study Collaborative, G. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. *Lancet* 2002, 360, 23–33.

151. Buijsse, B.; Jacobs, D.R., Jr; Steffen, L.M.; Kromhout, D.; Gross, M.D. Plasma Ascorbic Acid, A Priori Diet Quality Score, and Incident Hypertension: A Prospective Cohort Study. *PLoS ONE* 2015, 10, e0144920. [CrossRef]

152. Yochum, L.A.; Folsom, A.R.; Kushi, L.H. Intake of antioxidant vitamins and risk of death from stroke in postmenopausal women. *Am. J. Clin. Nutr.* 2000, 72, 476–483. [CrossRef]

153. Del Rio, D.; Agnoli, C.; Pellegrini, N.; Krogh, V.; Brighenti, F.; Mazzeto, T.; Masala, G.; Bendinelli, B.; Berrino, F.; Sieri, S.; et al. Total antioxidant capacity of the diet is associated with lower risk of ischemic stroke in a large Italian cohort. *J. Nutr.* 2011, 141, 118–123. [CrossRef]

154. Ye, Z.; Song, H. Antioxidant vitamins intake and the risk of coronary heart disease: Meta-analysis of cohort studies. *Eur. J. Cardiovasc. Prev. Rehabil.* 2008, 15, 26–34. [CrossRef] [PubMed]

155. Kubota, Y.; Iso, H.; Date, C.; Kikuchi, S.; Watanabe, Y.; Wada, Y.; Inaba, Y.; Tamakoshi, A.; Group, J.S. Dietary intakes of antioxidant vitamins and mortality from cardiovascular disease: The Japan Collaborative Cohort Study (JACC) study. *Stroke* 2011, 42, 1665–1672. [CrossRef] [PubMed]

156. Ye, Y.; Li, J.; Yuan, Z. Effect of antioxidant vitamin supplementation on cardiovascular outcomes: A meta-analysis of randomized controlled trials. *PLoS ONE* 2013, 8, e56803. [CrossRef] [PubMed]

157. Juraschek, S.P.; Guallar, E.; Appel, L.J.; Miller, E.R., 3rd. Effects of vitamin C supplementation on blood pressure: A meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* 2012, 95, 1079–1088. [CrossRef]

158. Chen, G.C.; Lu, D.B.; Pang, Z.; Liu, Q.F. Vitamin C intake, circulating vitamin C and risk of stroke: A meta-analysis of prospective studies. *J. Am. Heart Assoc.* 2013, 2, e000329. [CrossRef]

159. Ashor, A.W.; Lara, J.; Mathers, J.C.; Siervo, M. Effect of vitamin C on endothelial function in health and disease: A systematic review and meta-analysis of randomised controlled trials. *Atherosclerosis* 2014, 235, 9–20. [CrossRef]

160. Al-Khudairy, L.; Flowers, N.; Wheelhouse, R.; Ghannam, O.; Hartley, L.; Stranges, S.; Rees, K. Vitamin C supplementation for the primary prevention of cardiovascular disease. *Cochrane Database Syst. Rev.* 2017, 3, CD011114. [CrossRef]

161. Ran, L.; Zhao, W.; Tan, X.; Wang, H.; Mizuno, K.; Takagi, K.; Zhao, Y.; Bu, H. Association between Serum Vitamin C and the Blood Pressure: A Systematic Review and Meta-Analysis of Observational Studies. *Cardiov. Ther.* 2020, 2020, 4940673. [CrossRef]

162. Guan, Y.; Dai, P.; Wang, H. Effects of vitamin C supplementation on essential hypertension: A systematic review and meta-analysis. *Medicine* 2020, 99, e19274. [CrossRef]

163. Jayedi, A.; Rashidy-Pour, A.; Parohon, M.; Zargar, M.S.; Shab-Bidar, S. Dietary and circulating vitamin C, vitamin E, beta-carotene and risk of total cardiovascular mortality: A systematic review and dose-response meta-analysis of prospective observational studies. *Public Health Nutr.* 2019, 22, 1872–1887. [CrossRef]

164. Bird, J.K.; Murphy, R.A.; Ciappio, E.D.; McBurney, M.I. Risk of Deficiency in Multiple Concurrent Micronutrients in Children and Adults in the United States. *Nutrients* 2017, 9, 655. [CrossRef] [PubMed]

165. Santulli, G.; Cipolletta, E.; Sorrentino, D.; Del Giudice, C.; Anastasio, A.; Monaco, S.; Maione, A.S.; Condorelli, G.; Puca, A.; Trimarco, B.; et al. CaMK4 Gene Deletion Induces Hypertension. *J. Am. Heart Assoc.* 2012, 1, e010811. [CrossRef] [PubMed]

166. Iaccarino, G.; Ciccarelli, M.; Sorrentino, D.; Cipolletta, E.; Cerullo, V.; Iovino, G.L.; Paudice, A.; Elia, A.; Santulli, G.; Campanile, A.; et al. AKT participates in endothelial dysfunction in hypertension. *Circulation* 2004, 109, 2587–2593. [CrossRef] [PubMed]

167. Ross, R. The pathogenesis of atherosclerosis—An update. *N. Engl. J. Med.* 1986, 314, 488–500. [CrossRef] [PubMed]

168. Ross, R. Atherosclerosis—An inflammatory disease. *N. Engl. J. Med.* 1999, 340, 115–126. [CrossRef]
169. Sardu, C.; Gambardella, J.; Morelli, M.B.; Wang, X.; Marfella, R.; Santulli, G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J. Clin. Med. 2020, 9, 1417. [CrossRef]

170. Celermaiier, D.S.; Adams, M.R.; Clarkson, P.; Robinson, J.; McCredie, R.; Donald, A.; Deanfield, J.E. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N. Engl. J. Med. 1996, 334, 150–154. [CrossRef]

171. Marti, C.N.; Gheorghiaide, M.; Kalogeropoulos, A.P.; Georgiopoulou, V.V.; Quyyumi, A.A.; Butler, J. Endothelial dysfunction, arterial stiffness, and heart failure. J. Am. Coll. Cardiol. 2012, 60, 1455–1469. [CrossRef]

172. Matarese, A.; Gambardella, J.; Sardu, C.; Santulli, G. miR-98 Regulates TMPRSS2 Expression in Human Endothelial Cells: Key Implications for COVID-19. Biomedicines 2020, 8, 462. [CrossRef]

173. Aquila, G.; Morelli, M.B.; Vecelli Dalla Sega, F.; Fortini, F.; Nigro, P.; Caliceti, C.; Ferracin, M.; Negrini, M.; Panunzi, A.; Bonora, M.; et al. Heart rate reduction with ivabradine in the early phase of atherosclerosis is protective in the endothelium of ApoE-deficient mice. J. Physiol. Pharmacol. 2018, 69, 35–52.

174. Gambardella, J.; Sorriento, D.; Bova, M.; Rusciano, M.; Loffredo, S.; Wang, X.; Petraroji, A.; Carucci, L.; Mormile, I.; Oliveti, M.; et al. Role of Endothelial G Protein-Coupled Receptor Kinase 2 in Angioedema. Hypertension 2020, 76, 1625–1636. [CrossRef] [PubMed]

175. Sorriento, D.; Santulli, G.; Del Giudice, C.; Anastasio, A.; Trimarco, B.; Iaccarino, G. Endothelial cells are able to synthesize and release catecholamines both in vitro and in vivo. Hypertension 2012, 60, 129–136. [CrossRef] [PubMed]

176. Gambardella, J.; Morelli, M.B.; Wang, X.J.; Santulli, G. Pathophysiological mechanisms underlying the beneficial effects of physical activity in hypertension. J. Clin. Hypertens. 2020, 22, 291–295. [CrossRef] [PubMed]

177. Munro, J.M.; Cotran, R.S. The pathogenesis of atherosclerosis: Atherogenesis and inflammation. Lab. Investig. 1988, 58, 249–261. [PubMed]

178. Forman, J.P.; Choi, H.; Curhan, G.C. Fructose and vitamin C intake do not influence risk for developing hypertension. J. Am. Soc. Nephrol. 2009, 20, 863–871. [CrossRef] [PubMed]

179. Block, G.; Jensen, C.D.; Norkus, E.P.; Hudes, M.; Crawford, P.B. Vitamin C in plasma is inversely related to blood pressure and change in blood pressure during the previous year in young Black and White women. Nutr. J. 2008, 7, 35. [CrossRef] [PubMed]

180. Bruno, R.M.; Daghini, E.; Ghiodoni, L.; Sudano, I.; Rugani, I.; Varanini, M.; Passino, C.; Emdin, M.; Taddei, S. Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients. Am. J. Clin. Nutr. 2012, 96, 302–308. [CrossRef]

181. Heitger, T.; Just, H.; Munzel, T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996, 94, 6–9. [CrossRef]

182. Fuller, C.J.; Grundy, S.M.; Norkus, E.P.; Jialal, I. Effect of ascorbate supplementation on low density lipoprotein oxidation in smokers. Atherosclerosis 1996, 119, 139–150. [CrossRef]

183. Van Huydonck, P.G.; Schouten, E.G.; Manuel, Y.K.B.; van Campenhout, A.; Hoppenbrouwers, K.P.; Temme, E.H. Does vitamin C supplementation influence the levels of circulating oxidized LDL, sCAM-1, sVCAM-1 and vWF-antigen in healthy male smokers? Eur. J. Clin. Nutr. 2004, 58, 1587–1593. [CrossRef]

184. Salonen, J.T.; Nyyssonen, K.; Salonen, R.; Lakka, H.M.; Kaikkonen, J.; Pirkkala-Sarataho, E.; Voutilainen, S.; Lakka, T.A.; Rissanen, T.; Leskinen, L.; et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASP) study: A randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J. Intern. Med. 2000, 248, 377–386. [CrossRef] [PubMed]

185. Valls, N.; Gormaz, J.G.; Aguayo, R.; Gonzalez, J.; Brito, R.; Hasson, D.; Libyu, M.; Ramos, C.; Carrasco, R.; Prieto, J.C.; et al. Amelioration of persistent left ventricular function impairment through increased plasma ascorbate levels following myocardial infarction. Redox Rep. 2016, 21, 75–83. [CrossRef] [PubMed]

186. Ranadive, S.M.; Joyner, M.J.; Walker, B.G.; Taylor, J.L.; Casey, D.P. Effect of vitamin C on hyperoxia-induced vasoconstriction in exercising skeletal muscle. J. Appl. Physiol. 2014, 117, 1207–1211. [CrossRef] [PubMed]

187. Barak, O.F.; Caljkusic, K.; Hoiland, R.L.; Ainslie, P.N.; Thom, S.R.; Yang, M.; Jovanov, P.; Dujic, Z. Differential influence of vitamin C on the peripheral and cerebral circulation after diving and exposure to hyperoxia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2018, 315, R759–R767. [CrossRef]
188. Johnson, B.D.; Mather, K.J.; Newcomer, S.C.; Mickleborough, T.D.; Wallace, J.P. Vitamin C prevents the acute decline of flow-mediated dilation after altered shear rate patterns. *Appl. Physiol. Nutr. Metab.* 2013, 38, 268–274. [CrossRef]

189. Thosar, S.S.; Bielko, S.L.; Wiggins, C.C.; Klauunig, J.E.; Mather, K.J.; Wallace, J.P. Antioxidant vitamin C prevents decline in endothelial function during sitting. *Med. Sci. Monit.* 2015, 21, 1015–1021.

190. De Marchi, S.; Prior, M.; Rigoni, A.; Zecchetto, S.; Rulfo, F.; Arosio, E. Ascorbic acid prevents vascular dysfunction induced by oral glucose load in healthy subjects. *Eur. J. Intern. Med.* 2012, 23, 54–57. [CrossRef]

191. Batista, G.M.S.; Rocha, H.N.M.; Storch, A.S.; Garcia, V.P.; Teixeira, G.F.; Mentzinger, J.; Gomes, E.A.C.; Velasco, L.L.; Nobrega, A.C.L.; Rocha, N.G. Ascorbic acid inhibits vascular remodeling induced by mental stress in overweight/obese men. *Life Sci.* 2020, 250, 117554. [CrossRef]

192. Plotnick, M.D.; D’Urzo, K.A.; Gurd, B.J.; Pyke, K.E. The influence of vitamin C on the interaction between acute mental stress and endothelial function. *Eur. J. Appl. Physiol.* 2017, 117, 1657–1668. [CrossRef]

193. Richards, J.C.; Cereclius, A.R.; Larson, D.G.; Dinennno, F.A. Acute ascorbic acid ingestion increases skeletal muscle blood flow and oxygen consumption via local vasodilation during graded handgrip exercise in older adults. *Am. J. Physiol. Heart Circ. Physiol.* 2015, 309, H360–H368. [CrossRef]

194. Meredith, M.E.; Qu, Z.C.; May, J.M. Ascorbate reverses high glucose- and RAGE-induced leak of the endothelial permeability barrier. *Biochem. Biophys. Res. Commun.* 2014, 445, 30–35. [CrossRef] [PubMed]

195. Parker, W.H.; Rhea, E.M.; Qu, Z.C.; May, J.M. Intracellular ascorbate tightens the endothelial permeability barrier through Epac1 and the tubulin cytoskeleton. *Am. J. Physiol. Cell Physiol.* 2016, 311, C652–C662. [CrossRef] [PubMed]

196. Uller, E.; Parker, W.H.; Raj, A.; Qu, Z.C.; May, J.M. Ascorbic acid prevents VEGF-induced increases in endothelial permeability barrier. *Mol. Cell. Biochem.* 2016, 412, 73–79. [CrossRef] [PubMed]

197. Chelazzi, C.; Villa, G.; Mancinelli, P.; De Gaudio, A.R.; Adembri, C. Glycocalyx and sepsis-induced alterations in vascular permeability. *Crit. Care* 2015, 19, 26. [CrossRef]

198. Fernandez-Sarmiento, J.; Salazar-Pelaez, L.M.; Carcillo, J.A. The Endothelial Glycocalyx: A Fundamental Determinant of Vascular Permeability in Sepsis. *Pediatr. Crit. Care Med.* 2020, 21, e291–e300. [CrossRef]

199. Kang, Q.; Chen, Y.; Zhang, X.; Yu, G.; Wan, X.; Wang, J.; Bo, L.; Zhu, K. Heat shock protein A12B protects against sepsis-induced impairment in vascular endothelial permeability. *J. Surg. Res.* 2016, 202, 87–94. [CrossRef]

200. Li, Z.; Yin, M.; Zhang, H.; Ni, W.; Pierce, R.W.; Zhou, H.J.; Min, W. BMX Represses Thrombin-PAR1-Mediated Endothelial Permeability and Vascular Leakage During Early Sepsis. *Circ. Res.* 2020, 126, 471–485. [CrossRef]

201. Mironova, G.D.; Belosludtseva, N.V.; Ananyan, M.A. Prospects for the use of regulators of oxidative stress in the comprehensive treatment of the novel Coronavirus Disease 2019 (COVID-19) and its complications. *Eur. Rev. Med. Pharmacol. Sci.* 2020, 24, 8585–8591.

202. Schonrich, G.; Raffrey, M.J.; Samstag, Y. Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. *Adv. Biol. Regul.* 2020, 77, 100741. [CrossRef]

203. Suhaul, S.; Zajac, J.; Fossum, C.; Lowater, H.; McCracken, C.; Severson, N.; Laatsch, B.; Narkiewicz-Jodko, A.; Johnson, B.; Liebau, J.; et al. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. *Protein J.* 2020, 1–13. [CrossRef]

204. Montel-Hagen, A.; Kinet, S.; Manel, N.; Mongellaz, C.; Prohaska, R.; Battini, J.L.; Delaunay, J.; Sitbon, M.; Taylor, N. Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C. *Cell 2008*, 132, 1039–1048. [CrossRef] [PubMed]

205. Wang, Y.; Russo, T.A.; Kwon, O.; Chanock, S.; Rumsey, S.C.; Levine, M. Ascorbate recycling in human neutrophils: Induction by bacteria. *Proc. Natl. Acad. Sci. USA* 1997, 94, 13816–13819. [CrossRef] [PubMed]

206. Bauer, S.R.; Kapoor, A.; Rath, M.; Thomas, S.A. What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19? *Cleve. Clin. J. Med.* 2020. [CrossRef] [PubMed]

207. Carr, A.C.; Rowe, S. The Emerging Role of Vitamin C in the Prevention and Treatment of COVID-19. *Nutrients* 2020, 12, 3286. [CrossRef]

208. Gillani, S.W.; Sulaiman, S.A.S.; Abdul, M.I.M.; Baig, M.R. Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12-month single blind multicenter randomized control trial. *Cardiovasc. Diabetol.* 2017, 16, 103. [CrossRef]
209. Ceriello, A.; Novials, A.; Ortega, E.; Canivell, S.; La Sala, L.; Pujadas, G.; Bucciarelli, L.; Rondinelli, M.; Genovese, S. Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetes. *Diabetes Care* 2013, 36, 4104–4108. [CrossRef]

210. Bae, M.; Kim, H. Mini-Review on the Roles of Vitamin C, Vitamin D, and Selenium in the Immune System against COVID-19. *Molecules* 2020, 25, 5346. [CrossRef]

211. Bronte, V.; Zanovello, P. Regulation of immune responses by L-arginine metabolism. *Nat. Rev. Immunol.* 2005, 5, 641–654. [CrossRef]

212. Wijnands, K.A.; Castermans, T.M.; Hommen, M.P.; Meesters, D.M.; Poeze, M. Arginine and citrulline and the immune response in sepsis. *Nutrients* 2015, 7, 1426–1463. [CrossRef]

213. Kuck, J.L.; Bastarache, J.A.; Shaver, C.M.; Fessel, J.P.; Dikalov, S.I.; May, J.M.; Ware, L.B. Ascorbic acid attenuates endothelial permeability triggered by cell-free hemoglobin. *Biochem. Biophys. Res. Commun.* 2018, 495, 433–437. [CrossRef]

214. Lundblad, C.; Bentzer, P. Effects of L-arginine on cerebral blood flow, microvascular permeability, number of perfused capillaries, and brain water content in the traumatized mouse brain. *Microvasc. Res.* 2007, 74, 1–8. [CrossRef] [PubMed]

215. May, J.M.; Qu, Z.C. Nitric oxide mediates tightening of the endothelial barrier by ascorbic acid. *Biochem. Biophys. Res. Commun.* 2011, 404, 701–705. [CrossRef] [PubMed]

216. Carr, A.C.; Maggini, S. Vitamin C and Immune Function. *Nutrients* 2017, 9, 1211. [CrossRef] [PubMed]

217. Yokoyama, T.; Date, C.; Kokubo, Y.; Yoshiike, N.; Matsumura, Y.; Tanaka, H. Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community. The Shibata study. *Stroke* 2000, 31, 2287–2294. [CrossRef]

218. Michels, A.J.; Frei, B. Myths, artifacts, and fatal flaws: Identifying limitations and opportunities in vitamin C research. *Nutrients* 2013, 5, 5161–5192. [CrossRef]

219. Henriquez-Sanchez, P.; Sanchez-Villegas, A.; Doreste-Alonso, J.; Ortiz-Andrellucchi, A.; Pfimer, K.; Serra-Majem, L. Dietary assessment methods for micronutrient intake: A systematic review on vitamins. *Br. J. Nutr.* 2009, 102, S10–S37. [CrossRef]

220. Cahill, L.E.; El-Soehmy, A. Vitamin C transporter gene polymorphisms, dietary vitamin C and serum ascorbic acid. *J. Nutrigenet. Nutrigenom.* 2009, 2, 292–301. [CrossRef]

221. Horska, A.; Mislanova, C.; Bonassi, S.; Ceppi, M.; Volkova, K.; Dusinska, M. Vitamin C levels in blood are influenced by polymorphisms in glutathione S-transferases. *Eur. J. Nutr.* 2011, 50, 437–446. [CrossRef]

222. Cahill, L.E.; El-Soehmy, A. Haptoglobin genotype modifies the association between dietary vitamin C and serum ascorbic acid deficiency. *Am. J. Clin. Nutr.* 2010, 92, 1494–1500. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).